More detail below the table, on another page....
I hope MedAdvisor is accruing interest against this payment.
They also state it’s one of their largest customers, which would suggest it is a big pharmaceutical. A big pharma is likely to have a bigger balance sheet than MDR. A 6 month+ delay smells like a dispute.
This return to normalized debtor levels will result in FY22 Q1 cash flows being positively impacted from this payment in July and improved payment arrangements going forward. As a result, the cash balance has now lifted to ~$14.4m for Q3, up from $7.2m at 30 June.
Add to My Watchlist
What is My Watchlist?
